dr reddy's glp-1 drugs portfolio 2025 With the launch of our oral semaglutide biosimilar, Obeda® tablets, we are broadening our GLP‑1 to offer more choice and flexibility for patients. Oral semaglutide, as a convenient and flexible option 10 Stocks Set to Ride

Wegovy carries a higher list price ($1,349.02) reflecting its obesity treatment indication versus Ozempic ($997.58) for diabetes

and (3) the previously mentioned outcome measures

The texts further explain that the connection is driven by shared pathophysiological mechanisms, including chronic inflammation, oxidative stress, and the overexpression of Vascular Endothelial Growth Factor (VEGF)

Collectively, these studies indicate that the antihypertensive effect of GLP-1 is mediated by its natriuretic effect on the kidneys, vasodilation on endothelial cells, and reduction of sympathetic activity on brain stem catecholamine neurons (95)